Article
Disclosure pattern and follow-up after the molecular diagnosis of BRCA/CHEK2 mutations.
Journal of genetic counseling - 1 Apr 2014
Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B
Abstract excerpt
Five to 10% of all breast cancer cases are due to mutations of high penetrance susceptibility genes, especially BRCA1 and BRCA2. In families with known BRCA mutations, disclosure of genetic test results could induce relatives to undergo genetic testing themselves and adopt cancer risk management strategies, if necessary. This study examines disclosure patterns of individuals tested for mutations in the BRCA1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
